Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
Open Access
- 6 March 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 96 (6), 952-959
- https://doi.org/10.1038/sj.bjc.6603656
Abstract
The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma (SCC) of the head and neck. Most patients, however, do not respond or develop resistance to this agent. Mammalian target of rapamycin (mTOR) is involved in the pathogenesis of SCC of the head and neck (SCCHN). This study aimed to determine if targeting mTOR in combination with EGFR is effective in SCC, and to develop early pharmacodynamic markers of efficacy. Two SCC cell lines, one resistant (HEP2) and one of intermediate susceptibility (Detroit 562) to EGFR inhibitors, were xenografted in vivo and treated with an mTOR inhibitor (temsirolimus), an EGFR inhibitor (erlotinib) or a combination of both. Temsirolimus exerted superior growth arrest in both cell lines than erlotinib. The combined treatment resulted in synergistic antitumor effects in the Detroit 562 cell line. Immunohistochemical assessment of pharmacodynamic effects in fine-needle aspiration (FNA) biopsies early after treatment using phospho MAPK, Phospho-P70 and Ki67 as end points demonstrated pathway abrogation in the Detroit 562 tumours treated with the combination, the only group where regressions were seen. In conclusion, an mTOR inhibitor showed antitumor activity in EGFR-resistant SCC cell lines. Marked antitumor effects were associated with dual pathway inhibition, which were detected by early FNA biopsies.Keywords
This publication has 24 references indexed in Scilit:
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathwayAnnals of Oncology, 2004
- Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)Cancer Research, 2004
- Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2004
- Acquired resistance to EGFR inhibitors: mechanisms and prevention strategiesInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic CancerClinical Cancer Research, 2004
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc ExpressionPublished by Elsevier BV ,2004
- Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene, 2003
- Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.2001